Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
作者信息
Cherney David Z I, Charbonnel Bernard, Cosentino Francesco, Dagogo-Jack Samuel, McGuire Darren K, Pratley Richard, Shih Weichung J, Frederich Robert, Maldonado Mario, Pong Annpey, Cannon Christopher P
机构信息
University of Toronto, Toronto, ON, Canada.
University of Nantes, Nantes, France.
出版信息
Diabetologia. 2022 May;65(5):908-911. doi: 10.1007/s00125-021-05623-z. Epub 2022 Mar 3.
Abstract
摘要
相似文献
1
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].恩格列净、肾脏保护作用及肌肉消耗可能造成的混淆。对格罗特霍夫D、波斯特A、甘斯ROB等人的回复[信件]
Diabetologia. 2022 May;65(5):908-911. doi: 10.1007/s00125-021-05623-z. Epub 2022 Mar 3.
2
Ertugliflozin, renoprotection and potential confounding by muscle wasting.恩格列净、肾脏保护作用以及肌肉消耗导致的潜在混杂因素
Diabetologia. 2022 May;65(5):906-907. doi: 10.1007/s00125-021-05614-0. Epub 2021 Dec 23.
3
The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.肾功能损害对2型糖尿病患者中恩格列净药代动力学和药效学的影响。
J Clin Pharmacol. 2017 Nov;57(11):1432-1443. doi: 10.1002/jcph.955. Epub 2017 Jul 13.
4
Ertugliflozin for the treatment of type 2 diabetes.恩格列净用于治疗2型糖尿病。
Drugs Today (Barc). 2019 Mar;55(3):167-175. doi: 10.1358/dot.2019.55.3.2904972.
5
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.依帕列净对 2 型糖尿病合并已确诊动脉粥样硬化性心血管疾病患者心力衰竭相关事件的疗效：VERTIS CV 试验结果。
Circulation. 2020 Dec 8;142(23):2205-2215. doi: 10.1161/CIRCULATIONAHA.120.050255. Epub 2020 Oct 7.
6
Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus.依帕列净：用于治疗 2 型糖尿病的 SGLT-2 抑制剂市场的新选择。
Ann Pharmacother. 2019 May;53(5):478-485. doi: 10.1177/1060028018818829. Epub 2018 Dec 7.
7
Ertugliflozin as a monotherapy for the treatment of type 2 diabetes.依帕列净单药治疗 2 型糖尿病。
Expert Opin Pharmacother. 2018 Nov;19(16):1841-1847. doi: 10.1080/14656566.2018.1525360. Epub 2018 Sep 24.
8
Ertugliflozin: First Global Approval.依帕列净：全球首次获批。
Drugs. 2018 Mar;78(4):513-519. doi: 10.1007/s40265-018-0878-6.
9
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.厄格列净对 2 型糖尿病患者血压的影响：一项随机对照试验的事后汇总分析。
Cardiovasc Diabetol. 2019 May 7;18(1):59. doi: 10.1186/s12933-019-0856-7.
10
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.SGLT2 抑制剂依格列净在 2 型糖尿病合并 3 期慢性肾脏病患者中的血糖疗效和安全性：来自 VERTIS CV 随机试验的分析。
BMJ Open Diabetes Res Care. 2021 Oct;9(1). doi: 10.1136/bmjdrc-2021-002484.
引用本文的文献
1
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.衰弱、多病共存与多重用药：来自恩格列净治疗慢性肾脏病（EMPA-KIDNEY）试验的探索性分析
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1119-1129. doi: 10.2215/CJN.0000000000000498. Epub 2024 Jun 27.
本文引用的文献
1
Ertugliflozin, renoprotection and potential confounding by muscle wasting.恩格列净、肾脏保护作用以及肌肉消耗导致的潜在混杂因素
Diabetologia. 2022 May;65(5):906-907. doi: 10.1007/s00125-021-05614-0. Epub 2021 Dec 23.
2
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有 2 型糖尿病的慢性肾脏病患者肾功能下降速率的影响：来自 DAPA-CKD 试验的预先指定分析。
Lancet Diabetes Endocrinol. 2021 Nov;9(11):743-754. doi: 10.1016/S2213-8587(21)00242-4. Epub 2021 Oct 4.
3
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.达格列净在 4 期慢性肾脏病中的作用。
J Am Soc Nephrol. 2021 Sep;32(9):2352-2361. doi: 10.1681/ASN.2021020167. Epub 2021 Jul 16.
4
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus.达格列净增加 2 型糖尿病患者的瘦肉组织与总体重比值。
Nutr Diabetes. 2021 Jun 12;11(1):17. doi: 10.1038/s41387-021-00160-5.
5
Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.每日两次艾塞那肽与达格列净单药及联合治疗肥胖 2 型糖尿病患者肾功能标志物的影响：一项随机对照临床试验的预设二次分析。
Diabetes Obes Metab. 2021 Aug;23(8):1851-1858. doi: 10.1111/dom.14410. Epub 2021 May 14.
6
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.厄格列净对 2 型糖尿病患者肾脏复合结局、肾功能和蛋白尿的影响：来自随机 VERTIS CV 试验的分析。
Diabetologia. 2021 Jun;64(6):1256-1267. doi: 10.1007/s00125-021-05407-5. Epub 2021 Mar 4.
7
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
8
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.在 2 型糖尿病患者中使用依格列净的心血管结局。
N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23.
9
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
10
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.达格列净对非糖尿病慢性肾脏病患者蛋白尿的影响（DIAMOND）：一项随机、双盲、交叉试验。
Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5.
Zotero 插件